Bo-Wen Lin
Impact in
-
- Diabetes Treatment and Management
- Cancer Research top 10%
- Cancer, Hypoxia, and Metabolism
Papers in
-
- Cardiomyopathy and Myosin Studies 3
- Renin-Angiotensin System Studies 2
-
- ATP Synthase and ATPases Research 2
- Co-authors
- Shokei Kim‐Mitsuyama (10 shared papers)Yu Hasegawa (10 shared papers)Nobutaka Koibuchi (9 shared papers)Daisuke Sueta (6 shared papers)Ken Uekawa (5 shared papers)Hiroaki Kusaka (6 shared papers)Kensuke Toyama (5 shared papers)Takashi Nakagawa (4 shared papers)
In The Last Decade
Bo-Wen Lin
35 papers receiving 1.2k citations
Bo-Wen Lin's Hit Papers
Peers
Comparison fields: 5 of 90
- Endocrinology, Diabetes and Metabolism 329
- Cancer Research 172
- Neurology 97
- Cardiology and Cardiovascular Medicine 176
- Biological Psychiatry 18
Countries citing papers authored by Bo-Wen Lin
This map shows the geographic impact of Bo-Wen Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bo-Wen Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bo-Wen Lin more than expected).
Fields of papers citing papers by Bo-Wen Lin
This network shows the impact of papers produced by Bo-Wen Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bo-Wen Lin. The network helps show where Bo-Wen Lin may publish in the future.
Co-authors
The 25 scholars most cited alongside Bo-Wen Lin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 36 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice Hit paper breakdown → | 2014 | 346 |
| 2 | 2011 | 119 | |
| 3 | 2016 | 94 | |
| 4 | 2015 | 68 | |
| 5 | 2015 | 64 | |
| 6 | 2017 | 59 | |
| 7 | 2008 | 55 | |
| 8 | 2020 | 53 | |
| 9 | 2014 | 52 | |
| 10 | 2017 | 27 | |
| 11 | 2017 | 23 | |
| 12 | 2022 | 22 | |
| 13 | 2015 | 21 | |
| 14 | 2014 | 20 | |
| 15 | 2021 | 19 | |
| 16 | 2014 | 19 | |
| 17 | 2012 | 17 | |
| 18 | 2022 | 17 | |
| 19 | 2019 | 14 | |
| 20 | 2022 | 13 |
About Bo-Wen Lin
Bo-Wen Lin is a scholar working on Cardiology and Cardiovascular Medicine, Molecular Biology, Cancer Research, Surgery and Oncology, having authored 36 papers that have together received 1.2k indexed citations. Recurring topics across this work include Cancer-related molecular mechanisms research (3 papers), Neurological Disease Mechanisms and Treatments (3 papers), Cardiomyopathy and Myosin Studies (3 papers), Cancer, Hypoxia, and Metabolism (3 papers), Renin-Angiotensin System Studies (2 papers), HER2/EGFR in Cancer Research (2 papers), Colorectal Cancer Treatments and Studies (2 papers) and ATP Synthase and ATPases Research (2 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (329 citations), Cancer Research (172 citations), Neurology (97 citations), Cardiology and Cardiovascular Medicine (176 citations) and Biological Psychiatry (18 citations). Bo-Wen Lin has collaborated with scholars based in Taiwan, China and Japan. Frequent co-authors include Shokei Kim‐Mitsuyama, Yu Hasegawa, Nobutaka Koibuchi, Daisuke Sueta, Ken Uekawa, Hiroaki Kusaka, Kensuke Toyama, Takashi Nakagawa, Mingjie Ma and Jenq-Chang Lee. Their work appears in journals such as Cardiovascular Diabetology, Journal of the American Heart Association, World Journal of Surgical Oncology, Theranostics and Cell Death Discovery.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.